XIFYRM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xifyrm, and when can generic versions of Xifyrm launch?
Xifyrm is a drug marketed by Azurity and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in XIFYRM is meloxicam. There is one drug master file entry for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the meloxicam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xifyrm
A generic version of XIFYRM was approved as meloxicam by AVONDALE PHARMS on June 1st, 2004.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for XIFYRM?
- What are the global sales for XIFYRM?
- What is Average Wholesale Price for XIFYRM?
Summary for XIFYRM
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 2,542 |
| What excipients (inactive ingredients) are in XIFYRM? | XIFYRM excipients list |
| DailyMed Link: | XIFYRM at DailyMed |
Pharmacology for XIFYRM
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
US Patents and Regulatory Information for XIFYRM
XIFYRM is protected by one US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | XIFYRM | meloxicam | SOLUTION;INTRAVENOUS | 218395-001 | Jun 5, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
